Genovate Biotechnology Co Ltd - Asset Resilience Ratio
Genovate Biotechnology Co Ltd (4130) has an Asset Resilience Ratio of 20.77% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read how much debt does Genovate Biotechnology Co Ltd carry for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2015–2025)
This chart shows how Genovate Biotechnology Co Ltd's Asset Resilience Ratio has changed over time. See Genovate Biotechnology Co Ltd shareholders equity for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Genovate Biotechnology Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 4130 market cap overview.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 0% |
| Short-term Investments | NT$312.92 Million | 20.77% |
| Total Liquid Assets | NT$312.92 Million | 20.77% |
Asset Resilience Insights
- Good Liquidity Position: Genovate Biotechnology Co Ltd maintains a healthy 20.77% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Genovate Biotechnology Co Ltd Industry Peers by Asset Resilience Ratio
Compare Genovate Biotechnology Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Argen-X
F:1AE |
Biotechnology | 25.67% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
BrightGene Bio Medical Technology C
SHG:688166 |
Biotechnology | 1.00% |
|
Dashenlin Pharm Grp Co Ltd
SHG:603233 |
Biotechnology | 0.02% |
|
Staidson Beijing Biopharma
SHE:300204 |
Biotechnology | 7.93% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 41.25% |
|
Ardelyx Inc
NASDAQ:ARDX |
Biotechnology | 41.14% |
|
Xiangxue Pharmaceutical
SHE:300147 |
Biotechnology | 0.05% |
Annual Asset Resilience Ratio for Genovate Biotechnology Co Ltd (2015–2025)
The table below shows the annual Asset Resilience Ratio data for Genovate Biotechnology Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 20.77% | NT$312.92 Million ≈ $9.86 Million |
NT$1.51 Billion ≈ $47.46 Million |
+1.92pp |
| 2024-12-31 | 18.86% | NT$299.87 Million ≈ $9.45 Million |
NT$1.59 Billion ≈ $50.10 Million |
-3.59pp |
| 2023-12-31 | 22.45% | NT$359.27 Million ≈ $11.32 Million |
NT$1.60 Billion ≈ $50.42 Million |
+3.09pp |
| 2022-12-31 | 19.36% | NT$302.88 Million ≈ $9.54 Million |
NT$1.56 Billion ≈ $49.29 Million |
+6.76pp |
| 2021-12-31 | 12.60% | NT$190.98 Million ≈ $6.02 Million |
NT$1.52 Billion ≈ $47.75 Million |
0.00pp |
| 2020-12-31 | 12.60% | NT$197.98 Million ≈ $6.24 Million |
NT$1.57 Billion ≈ $49.49 Million |
-3.74pp |
| 2019-12-31 | 16.35% | NT$257.10 Million ≈ $8.10 Million |
NT$1.57 Billion ≈ $49.56 Million |
+1.82pp |
| 2018-12-31 | 14.52% | NT$252.10 Million ≈ $7.94 Million |
NT$1.74 Billion ≈ $54.69 Million |
-0.02pp |
| 2017-12-31 | 14.54% | NT$296.92 Million ≈ $9.35 Million |
NT$2.04 Billion ≈ $64.33 Million |
-3.82pp |
| 2016-12-31 | 18.37% | NT$486.00 Million ≈ $15.31 Million |
NT$2.65 Billion ≈ $83.37 Million |
-3.02pp |
| 2015-12-31 | 21.39% | NT$538.40 Million ≈ $16.96 Million |
NT$2.52 Billion ≈ $79.31 Million |
-- |
About Genovate Biotechnology Co Ltd
Genovate Biotechnology Co., Ltd. engages in the research, development, manufacture, production, and sale of products to prevent and treat diseases caused by viruses and bacteria in Taiwan. It provides drugs, APIs, intermediates, and release agents for the treatment of cardiovascular, esophageal, gastrointestinal, cancer, and autoimmune diseases; and controlled-release dosage forms of Western medi… Read more